Promising new drug blocks mutation in bone marrow cancers

Dec 09, 2008

Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.

The oral drug, called CYT387, was tested in mice as well as in human cells. In both cases, it blocked the growth of certain bone marrow cancers called myeloproliferative disorders, also referred to as MPDs.

The research will be presented Tuesday, Dec. 9, during the 50th annual American Society of Hematology conference in San Francisco.

"The drug was found to be very effective against a specific type of cancer cells, cancer cells which are driven by an enzyme mutation called JAK2-V617F. In the mouse model, the drug blocked JAK2-V617F, normalized blood counts and reduced enlarged spleens back to a normal size. It is a very promising compound," said Thomas Bumm, M.D., Ph.D., a member of the research team.

The drug works by binding to the V617F mutation in the JAK2 enzyme. Without this drug, the mutated JAK2 enzyme leads to MPDs. The "big three" MPDs include polycythemia vera, essential thrombocythemia and primary myelofibrosis. Until now there have been no FDA-approved targeted treatments for these diseases.

"Based on the efficacy that we demonstrated in the mouse model, there is a good chance that CYT387 will enter clinical trials as early as 2009. Those in greatest need include patients with myelofibrosis, a relentless disease for which there is currently no effective therapy. It is likely that JAK2 inhibitors will change the standard of care for these patients," said Michael Deininger, M.D., Ph.D., principal investigator and Head of the Hematological Malignancies Program Ph.D. He also is an associate professor of medicine (hematology/medical oncology), OHSU School of Medicine and a Scholar of the Leukemia & Lymphoma Society.

Researchers also discovered that CYT387 effectively blocks overproduction of inflammatory cytokines. Abnormal cells carrying the JAK2-V617F mutation produce a large amount of different inflammatory cytokines that help the cancer cells to grow and repress normal cells. In mice, the drug normalized 19 different inflammatory cytokine levels in the blood. The overproduction of cytokines can also be found in inflammatory conditions such as rheumatoid arthritis. This drug's effect on cytokines could benefit patients with inflammatory diseases, especially rheumatoid arthritis.

The next likely step will be to open clinical trials for people with MPD as soon as 2009 once formal preclinical toxicology studies are completed.

Source: Oregon Health & Science University

Explore further: Medical marijuana helpful for cancer-linked symptoms

add to favorites email to friend print save as pdf

Related Stories

Fingers pointed as climate talks deadlock

8 hours ago

Accusations flew at deadlocked UN climate talks in Lima on Saturday, as the United States warned that failure to compromise could doom the 22-year-old global forum.

Fun cryptography app pleases students and teachers

18 hours ago

Up on Google Play this week is Cryptoy...something that you might want to check out if you or someone you know wishes entry into the world of cryptography via an educational and fun app. You learn more about ciphers and keys; you ...

Recommended for you

Putting the brakes on cancer

12 hours ago

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

Peanut component linked to cancer spread

13 hours ago

Scientists at the University of Liverpool have found that a component of peanuts could encourage the spread and survival of cancer cells in the body.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.